Khiron Life Sciences Corp (OTCMKTS:KHRNF) is a vertically integrated medical cannabis company focused on research, cultivation, manufacturing and distribution of cannabinoid-based products. The company operates in compliance with Good Manufacturing Practices (GMP) and produces a range of therapeutic formulations, including oils, soft gel capsules and topicals, designed to address various patient needs in the medical and wellness markets.
The company’s proprietary product lines are developed through in-house research and formulated by its team of clinical and pharmaceutic specialists. Khiron operates a network of branded clinics and telemedicine platforms in Colombia, providing patient consultations, follow-up care and access to its licensed medicinal cannabis therapies. Through strategic partnerships and distribution agreements, Khiron’s products have also reached markets in Europe and Latin America.
Founded in 2013 and headquartered in Toronto, Khiron Life Sciences leverages cultivation facilities in Colombia to produce cannabis flower under controlled environmental conditions. The company pursues ongoing clinical trials and real-world evidence studies to support the efficacy and safety of its formulations. Khiron aims to advance patient education and expand access to cannabinoid therapies across underserved regions.
Under the leadership of founder and CEO Dr. Álvaro Torres, Khiron has grown from a domestic cultivator into a multinational life sciences enterprise. The management team combines expertise in pharmaceutical development, clinical research and regulatory affairs to navigate emerging cannabis markets and drive commercial expansion.
AI Generated. May Contain Errors.